An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of
XP21279 sustained release formulation [administered with Lodosyn® (carbidopa)] and Sinemet®
tablets in subjects with Parkinson's disease with Motor Fluctuations.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
XenoPort, Inc.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa